• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Cholesterol-containing lipid particles protect mice from lethal bacterial toxins

byJudith KandelandSarah Stapleton
November 7, 2014
in Chronic Disease, Infectious Disease, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Liposomes, small spheres composed of lipids, were engineered to contain artificially high cholesterol (Chol) concentrations to promote preferential binding of bacterial toxins to liposomes as opposed to cells.

2. Liposomes protected cells and mice from lethality induced by particular bacterial toxins.

Evidence Rating Level: 1 (Excellent)    

Study Rundown: Bacterial infections are usually treated with antibiotics, which kill most bacteria and often lead to the evolution of new, drug-resistant bacterial strains. In this work, the authors capitalized on the affinity of many bacterial toxins for Chol in the cell membrane to develop an alternative method for treating infection.

In this study, infected cells and mice were treated with liposomes composed of the lipids sphingomyelin (Sm) and Chol at varying ratios. Liposome Chol concentrations that were higher than those found in normal animal cell membranes led to preferential binding of the bacterial toxins to the liposomes. Chol:Sm liposomes protected several cell types from cell death following exposure to a variety of purified bacterial toxins. Monocyte survival after exposure to human pathogens, including particular strains of S. pyogenes, S. aureus, and S. pneumoniae, was dependent on both the specific pathogen and liposomes administered, suggesting that tailored liposome cocktails could be used to sequester multiple toxins released by different bacteria strains. Researchers found that liposome injection within ten hours of a lethal bacterial infection significantly improved mouse survival rates and reduced bacterial levels in blood. Liposome addition also appeared to decrease lung edemas in mice, which are induced by bacterial infection and the subsequent inflammatory response.

The short timescale in which liposome treatment was effective (within ten hours of bacterial infection) limits the translational potential of this work to treatment of human infection. However, these findings remain applicable to risky medical procedures, such as organ transplants, where sepsis is anticipated. Overall, this study introduces a novel, promising treatment method for a wide variety of bacterial infections that bypasses the consequence of bacterial drug resistance.

Click to read the study in Nature Biotechnology

RELATED REPORTS

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

Relevant Reading: New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis

In-Depth [animal study]: In in vitro investigations, monocyte survival was assessed by cell counting for 5-14 days following exposure to bacterial toxins. Chol:Sm liposomes with a 66% Chol content completely protected monocytes from total lethality induced by pneumolysin (PLY), phospholipase C (PLC), tetanolysin, streptolysin O, or α-hemolysin. Alternatively, endothelial and epithelial cells were transfected with a fluorescent indicator in the cytosol, and cell death was measured by loss of fluorescent signal indicating cell lysis by the toxins. Chol:Sm liposomes protected these cells from death following exposure to PLY or PLC. Monocytes exposed to bacterial culture supernatant, rather than purified toxins, were rescued from cell death in a manner dependent on both liposome content and specific pathogen exposure. Some strains required combinations of liposomes that contained varying lipid concentrations to completely rescue cell survival. For example, a Chol:Sm/Sm-only liposome cocktail fully protected monocytes following exposure to a strain of S. aureus, while Chol:Sm liposomes alone were only partially effective.

Several tens of mice were used to evaluate the protective quality of the liposomes in vivo. Chol:Sm/Sm-only liposome treatment of 100 mg/kg at 6 and 10 hours following intravenous injection with lethal S. pneumoniae doses increased mice survival rates (p<0.001 and p<0.05, respectively), and decreased blood bacterial levels (p<0.001 and p<0.01, respectively). In the case of lethal infection with S. aureus, treating mice with >100 mg/kg of Chol:Sm/Sm-only liposomes resulted in survival of all mice by 192 hours post infection (p<0.001). Lung edema was evaluated in two different ways, including comparing the wet and dry lung weights, and was reduced with liposome treatment (p<0.001).

More from this author: Noninvasive imaging method detects and evaluates size of metastases, Inhibition of key enzymes in the animal brain reduces drug relapse behavior

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: cholesteroltoxin
Previous Post

Shift work impacts cognition, but likely not permanently

Next Post

Dacomitinib may be effective in EGFR-associated lung cancer

RelatedReports

Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

November 22, 2022
Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

August 10, 2022
[Physician Comment] The extent of C. difficile infections may not differ in light of immune status
Gastroenterology

Oral microbiome therapy reduced Clostridioides difficile recurrence

January 24, 2022
Next Post
Dacomitinib may be effective in EGFR-associated lung cancer

Dacomitinib may be effective in EGFR-associated lung cancer

Olaparib monotherapy may be effective in advanced BRCA-associated cancers

Olaparib monotherapy may be effective in advanced BRCA-associated cancers

Patient Basics: Colposcopy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
  • The 2 Minute Medicine Podcast Episode 11
  • Wellness Check: Spirituality
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options